quinazolines has been researched along with regorafenib in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Printz, C | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Chen, Y; Chen, ZS; Huang, JR; Jiang, QW; Li, Y; Qin, WM; Qiu, JG; Shi, Z; Wang, K; Wang, YJ; Wei, MN; Yang, DH; Yang, Y; Zhang, WJ; Zheng, DW | 1 |
| Hsu, FT; Pan, PJ; Tsai, JJ | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W | 1 |
| Chu, E | 1 |
| Binglan, Z; Jing, Z; Rui, Z | 1 |
| Chen, J; Lin, H; Peng, Y; Wang, J | 1 |
| Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q | 1 |
| Cheng, Y; Du, FC; Duan, ZJ; Fang, FQ; Lei, W; Shi, KG | 1 |
| Jiang, FE; Liu, AN; Yu, CY; Zhang, HJ | 1 |
| Cao, Y; Chen, M; Li, J; Lu, M; Peng, Z; Qi, C; Shen, L; Wang, X; Wang, Z; Zhang, J; Zhang, Q | 1 |
7 review(s) available for quinazolines and regorafenib
| Article | Year |
|---|---|
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
Topics: Benzofurans; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Quinazolines; Treatment Outcome | 2019 |
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Quinazolines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2019 |
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Thymine; Time Factors; Trifluridine; Uracil | 2020 |
12 other study(ies) available for quinazolines and regorafenib
| Article | Year |
|---|---|
Strides in personalized medicine.
Topics: Afatinib; Gastrointestinal Stromal Tumors; Humans; Lung Neoplasms; Melanoma; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines | 2012 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response | 2015 |
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib | 2015 |
Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; NF-kappa B; Phenyl Ethers; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; X-Linked Inhibitor of Apoptosis Protein | 2017 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
How I treat chemorefractory metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Neoplasm Staging; Nivolumab; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thymine; Trastuzumab; Trifluridine; Uracil; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib.
Topics: Benzofurans; Colorectal Neoplasms; Humans; Indoles; Phenylurea Compounds; Pyridines; Quinazolines; Quinolines | 2020 |
Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
Topics: Antibodies, Monoclonal, Humanized; Benzofurans; Colorectal Neoplasms; DNA Mismatch Repair; Humans; Microsatellite Repeats; Phenylurea Compounds; Pilot Projects; Pyridines; Quinazolines; Retrospective Studies | 2021 |
Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Topics: Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Humans; Phenylurea Compounds; Prospective Studies; Pyridines; Quinazolines; Rectal Neoplasms; Retrospective Studies | 2022 |